Sign in

    Sally Yanchus

    Senior Research Analyst of Life Sciences at Water Tower Research

    Sally Yanchus is a Senior Research Analyst of Life Sciences at Water Tower Research, specializing in biotech and healthcare sector coverage. She covers companies such as Aspira Women's Health and has facilitated industry discussions with leaders like Aspira's CEO, contributing to expert insights in emerging biosimalar and life sciences markets. Yanchus has over two decades of combined buy- and sell-side experience, previously working at firms including Brookline Capital Markets and Tradewinds, and she joined Water Tower Research in April 2023. She has earned recognition for her industry expertise, though specific performance metrics such as TipRanks ratings or securities licenses have not been publicly disclosed.

    Sally Yanchus's questions to AWH leadership

    Sally Yanchus's questions to AWH leadership • Q4 2023

    Question

    Inquired about the status and potential launch timeline for the EndoCheck test, the level of awareness and interest among clinicians, and the current market for endometriosis therapies.

    Answer

    The company is evaluating the best launch strategy for EndoCheck, considering the rapid progress of EndoMDx. They are also submitting a grant application to the NIH, which has shown high interest. There is significant excitement from physicians for a noninvasive endometriosis test, as the only current diagnostic method is surgery. Existing therapies for endometriosis pain management are on the market, with more in development, which will increase the need for an effective diagnostic like EndoCheck.

    Ask Fintool Equity Research AI